Diagnostic information company Virality Diagnostics LLC reported on Thursday the receipt of the Food and Drug Administration's (FDA) Emergency Use Authorization (EUA) for a rapid COVID-19 antibody test manufactured by Biohit (Hefei) and distributed by Virality Diagnostics.
This test is a rapid SARS-CoV-2 lateral flow immunoassay (LFA) which detects both IgG and IgM antibodies with 98.5% accuracy.
It requires a simple finger-prick and only one drop of blood and delivers easily interpreted results within 15 minutes.
Recent trials involving over 1,500 patients at multiple sites, including Yale University and the National Cancer Institute (NCI), validated that Virality's tests exhibit near perfect (98.8%) specificity for the novel coronavirus and extremely high sensitivity (94.9%) for patients tested at least two weeks from symptom onset.
Krystal Biotech receives FDA approval for updated VYJUVEK label
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA